Author

F. Gruber

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Approach:benchmark study· 1 Assay:bulk RNA-seq· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Dervan· 1 shared A. Hope· 1 shared A. Pratapa· 1 shared A. Ratushny· 1 shared A. Thakurta· 1 shared B. A. Walker· 1 shared B. Bachmann· 1 shared B. Hayete· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Dervan

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The p-rpS6-zone delineates wounding response and the healing process

N. A. R. Ring, H. Dworak, B. Bachmann, B. Schaedl, K. Valdivieso, T. Rozmaric, P. Heimel, K. Schuetzenberger, G. Leinfellner, J. Ferguson, S. Drechsler, M. Mildner, M. Schosserer, P. Slezak, O. Meyuhas, , M. Ogrodnik

The paper identifies a p-rpS6-zone around wounds that marks the healing process and shows its role in tissue repair.

bioRxiv · Sep 27, 2022 · PreprintPhysiology

Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies

L. Armstrong, S. M. Lange, V. de Cesare, S. P. Matthews, R. S. Nirujogi, I. Cole, A. Hope, F. Cunningham, R. Toth, R. Mukherjee, D. Bojkova, F. Gruber, D. Gray, P. G. Wyatt, J. Cinatl, , Y. Kulathu

This study characterizes Nsp3 protease activity from SARS-CoV-2 and identifies nanobodies that inhibit PLpro with nanomolar affinity.

bioRxiv · Dec 9, 2020Biochemistry

Multiple Myeloma DREAM Challenge Reveals Epigenetic Regulator PHF19 As Marker of Aggressive Disease

M. J. Mason, C. Schinke, C. Eng, F. Towfic, F. Gruber, A. Dervan, B. S. White, A. Pratapa, Y. Guan, H. Chen, Y. Cui, B. Li, T. Yu, E. Chaibub Neto, K. Mavrommatis, , J. A. Guinney

The paper identifies PHF19 as a marker of aggressive multiple myeloma and shows a simple four-feature model performs as well as complex gene expression models.

bioRxiv · Aug 22, 2019Cancer Biology